Stereotactic Radiotherapy Plus Nivolumab in Patients with Locally Advanced Pancreatic Cancer: Results from Phase 1/2 Clinical CA209-9KH Trial

Authors

Institutions

Publication Details

Journal
Oncology and Therapy
Published
2024-10-23
DOI
https://doi.org/10.1007/s40487-024-00309-z
Citations
5
Primary Topic
Pancreatic and Hepatic Oncology Research
Type
article
Field-Weighted Citation Impact
1.41

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Stereotactic Radiotherapy Plus Nivolumab in Patients with Locally Advanced Pancreatic Cancer: Results from Phase 1/2 Clinical CA209-9KH Trial

Bohuslav Melichar, Radka Lohynská, Aml Mustafa Banni, Igor Sirák et al.
5 citations
Oncology and Therapy
Pancreatic and Hepatic Oncology Research
1.41
article

Stereotactic Radiotherapy Plus Nivolumab in Patients with Locally Advanced Pancreatic Cancer: Results from Phase 1/2 Clinical CA209-9KH Trial

Bohuslav Melichar, Radka Lohynská, Aml Mustafa Banni, Igor Sirák, Josef Dvořák, Milan Vošmik, Aleš Ryška, Johana Krempová, Beatrice Mohelníková-Duchoňová, Stanislav John
article en
5 citations

Abstract

No abstract available for this paper.
Oncology and TherapyVol. 12(4)
Charles University (CZ), University Hospital Olomouc (CZ), University Hospital Hradec Králové (CZ), Thomayer University Hospital (CZ), Palacký University Olomouc (CZ)
Bristol-Myers Squibb, Fakultní nemocnice Hradec Králové, Ministerstvo Zdravotnictví Ceské Republiky
Good health and well-being
Openalex Percentile: Top 15%
Pancreatic and Hepatic Oncology Research
1.41
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.